Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

Background/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level. PK studies of the switch to subcutaneous (SC) infliximab from in...

Descripció completa

Dades bibliogràfiques

Autors principals:	Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
Format:	Artigo
Idioma:	Inglês
Publicat:	Gastroenterology Council for Gut and Liver 2025-05-01
Col·lecció:	Gut and Liver
Matèries:	infliximab; pharmacokinetic model; intravenous; subcutaneous; inflammatory bowel diseases
Accés en línia:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl240503
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!